Welcome to our dedicated page for Orthofix Medical SEC filings (Ticker: OFIX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Orthofix Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Orthofix Medical's regulatory disclosures and financial reporting.
Orthofix Medical Inc. (OFIX) filed a Form 8-K reporting the results of its 18 June 2025 Annual Meeting of Shareholders.
Quorum: 35,364,307 of 39,180,306 eligible shares were present, comfortably exceeding the 19,590,154-share quorum requirement.
Director elections: All ten nominees—Alan L. Bazaar, Wayne Burris, Massimo Calafiore, Vickie L. Capps, Michael M. Finegan, Jason M. Hannon, John B. Henneman III, Charles R. Kummeth, Shweta Singh Maniar and Michael E. Paolucci—were elected for one-year terms ending at the 2026 meeting. Each candidate received substantially more “For” than “Against” votes.
Say-on-Pay: The advisory resolution approving executive compensation passed with 30,003,045 votes in favour versus 610,731 against and 9,569 abstentions.
Auditor ratification: Shareholders ratified Ernst & Young LLP as independent auditor for fiscal 2025 (35,017,551 votes in favour; 329,289 against; 17,467 abstentions).
Board committee appointments: Effective immediately, the Board unanimously appointed director Vickie L. Capps to the Audit & Finance Committee and to the Compensation & Talent Development Committee.
The filing contains no financial results, strategic transactions or other material events beyond routine governance disclosures.